Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05934851 · ClinicalTrials.gov registry record · NA
A Study Evaluating the Effect of Frozen-Section Directed Excision Surgery on Vulvar Dysplasia
A NA study of Vulvar Neoplasm and Dysplasia Vulvar, sponsored by Wake Forest University Health Sciences.
- Recruiting
- Registry status
- NA
- Development phase
- 112
- Enrollment target
- 1
- Study location
NCT05934851: Recruiting NA study of Vulvar Neoplasm and Dysplasia Vulvar, sponsored by Wake Forest University Health Sciences.
NCT05934851 is a NA study of Vulvar Neoplasm and Dysplasia Vulvar that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 112 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05934851, a NA study of Vulvar Neoplasm and Dysplasia Vulvar, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.
- RECRUITING
- Registry status
- NA
- Development phase
- 112 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to compare "Frozen-Section Directed Excision", which has been a proven method of surgery used in dermatology, versus the current, standard method called "Wide Local Excision" to treat high-grade vulvar dysplasia.
Primary Outcome
Comparison of rates of positive margins for VIN 2, VIN 3, VIN 2/3 or High-grade Dysplasia NOS in subjects who undergo standard of care Wide Local Excision versus subjects who undergo Frozen-Section Directed Excision
Conditions Studied
Interventions
- PROCEDURE Frozen-Section Directed Excision
- PROCEDURE Wide Local Excision
Study Locations (1)
North Carolina
- Levine Cancer Institute - Charlotte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2023-11-07 |
| Est. Completion | 2027-03-01 |
| Phase | NA |
What NCT05934851 shows while recruiting
NCT05934851 is an interventional study that assigns participants to a tested intervention. The registered 112 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower).
The record links to 2 conditions, with Vulvar Neoplasm appearing as the primary indexed condition, and to 2 interventions - of which Frozen-Section Directed Excision is the first listed.
NCT05934851 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT05934851 about?
NCT05934851 is a clinical study titled "A Study Evaluating the Effect of Frozen-Section Directed Excision Surgery on Vulvar Dysplasia". The purpose of this study is to compare "Frozen-Section Directed Excision", which has been a proven method of surgery used in dermatology, versus the current, standard method called "Wide Local Excision" to treat high-grade vulvar dysplasia.
What is the current status of trial NCT05934851?
This trial is currently recruiting. It is a NA study. The enrollment target is 112 participants. The study started on 2023-11-07. Estimated completion is 2027-03-01.
What conditions does trial NCT05934851 study?
This clinical trial studies the following conditions: Vulvar Neoplasm, Dysplasia Vulvar.
What interventions are being tested in trial NCT05934851?
The interventions under investigation include: Frozen-Section Directed Excision (PROCEDURE), Wide Local Excision (PROCEDURE).
Who is sponsoring clinical trial NCT05934851?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05934851 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05934851's enrollment target sits among peer trials
112 813th of 2000 higher than 1,185 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04511013 · 112 participants · Phase 2
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
- NCT04551560 · 112 participants · NA
Stress and Congestive Heart Failure
- NCT04872166 · 112 participants · Phase 1
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
- NCT05024773 · 112 participants · Phase 3
Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI